ANDRE SERRETTE: Open Payments
NPI 1558522888 · HEWLETT, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,909 in 87 payments from 18 companies in 2025. Trend: 2023 $1,126 · 2024 $1,685 · 2025 $1,909
Food & beverage: $1,909
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $276 |
| GlaxoSmithKline, LLC. | 14 | $266 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $194 |
| Axsome Therapeutics, Inc. | 6 | $174 |
| Novo Nordisk Inc | 7 | $160 |
| PFIZER INC. | 8 | $157 |
| Eisai Inc. | 4 | $108 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $92 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $91 |
| Lilly USA, LLC | 3 | $77 |
Products named: TRELEGY ELLIPTA, AIRSUPRA, XIFAXAN, Symbravo, Leqembi, JARDIANCE, CAPLYTA, PREVNAR 20.
Industry payments across NY — which companies pay providers there.
